The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
Juyong LiangZhijian JinJie KuangHaoran FengQiwu ZhaoZheyu YangLing ZhanBaiyong ShenJiqi YanWei CaiXi ChengWeihua QiuPublished in: British journal of cancer (2021)
The newly identified CXCL11-EGF-EGFR signalling provided mechanistic insight into the interaction between cancer and endothelial cells under hypoxia, and EGFR was a novel target. Anlotinib may be the encouraging therapeutic candidate in ATC.